Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo.

Fagerqvist T, Näsström T, Ihse E, Lindström V, Sahlin C, Tucker SM, Kasaryan A, Karlsson M, Nikolajeff F, Schell H, Outeiro TF, Kahle PJ, Lannfelt L, Ingelsson M, Bergström J.

Amyloid. 2013 Dec;20(4):233-44. doi: 10.3109/13506129.2013.835726. Epub 2013 Sep 20.

PMID:
24053224
2.

The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers.

Näsström T, Wahlberg T, Karlsson M, Nikolajeff F, Lannfelt L, Ingelsson M, Bergström J.

Biochem Biophys Res Commun. 2009 Jan 23;378(4):872-6. doi: 10.1016/j.bbrc.2008.12.005. Epub 2008 Dec 12.

PMID:
19070597
3.

Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.

Roberts RF, Wade-Martins R, Alegre-Abarrategui J.

Brain. 2015 Jun;138(Pt 6):1642-57. doi: 10.1093/brain/awv040. Epub 2015 Mar 1.

4.

The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties.

Näsström T, Fagerqvist T, Barbu M, Karlsson M, Nikolajeff F, Kasrayan A, Ekberg M, Lannfelt L, Ingelsson M, Bergström J.

Free Radic Biol Med. 2011 Feb 1;50(3):428-37. doi: 10.1016/j.freeradbiomed.2010.11.027. Epub 2010 Dec 1.

PMID:
21130160
5.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

6.

Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.

Tsika E, Moysidou M, Guo J, Cushman M, Gannon P, Sandaltzopoulos R, Giasson BI, Krainc D, Ischiropoulos H, Mazzulli JR.

J Neurosci. 2010 Mar 3;30(9):3409-18. doi: 10.1523/JNEUROSCI.4977-09.2010.

7.

Changes in secondary structure of α-synuclein during oligomerization induced by reactive aldehydes.

Cai Y, Lendel C, Österlund L, Kasrayan A, Lannfelt L, Ingelsson M, Nikolajeff F, Karlsson M, Bergström J.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):336-41. doi: 10.1016/j.bbrc.2015.06.154. Epub 2015 Jun 27.

PMID:
26129771
8.

Distinct α-synuclein strains differentially promote tau inclusions in neurons.

Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM.

Cell. 2013 Jul 3;154(1):103-17. doi: 10.1016/j.cell.2013.05.057.

9.

Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.

Schnack C, Danzer KM, Hengerer B, Gillardon F.

Neuroscience. 2008 Jul 17;154(4):1450-7. doi: 10.1016/j.neuroscience.2008.02.049. Epub 2008 Feb 29.

PMID:
18541383
10.

Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.

Fagerqvist T, Lindström V, Nordström E, Lord A, Tucker SM, Su X, Sahlin C, Kasrayan A, Andersson J, Welander H, Näsström T, Holmquist M, Schell H, Kahle PJ, Kalimo H, Möller C, Gellerfors P, Lannfelt L, Bergström J, Ingelsson M.

J Neurochem. 2013 Jul;126(1):131-44. doi: 10.1111/jnc.12175. Epub 2013 Feb 27.

11.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
12.

Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.

Welander H, Bontha SV, Näsström T, Karlsson M, Nikolajeff F, Danzer K, Kostka M, Kalimo H, Lannfelt L, Ingelsson M, Bergström J.

Biochem Biophys Res Commun. 2011 Aug 19;412(1):32-8. doi: 10.1016/j.bbrc.2011.07.027. Epub 2011 Jul 21.

PMID:
21798243
13.

Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein.

Bae EJ, Ho DH, Park E, Jung JW, Cho K, Hong JH, Lee HJ, Kim KP, Lee SJ.

Antioxid Redox Signal. 2013 Mar 1;18(7):770-83. doi: 10.1089/ars.2011.4429. Epub 2012 Sep 26.

14.

A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Myöhänen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, García-Horsman JA, Baekelandt V, Männistö PT, Lambeir AM.

Br J Pharmacol. 2012 Jun;166(3):1097-113. doi: 10.1111/j.1476-5381.2012.01846.x.

15.

Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.

Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL.

J Biol Chem. 2007 Feb 23;282(8):5862-70. Epub 2006 Dec 21.

16.

Hsp90 inhibits α-synuclein aggregation by interacting with soluble oligomers.

Daturpalli S, Waudby CA, Meehan S, Jackson SE.

J Mol Biol. 2013 Nov 15;425(22):4614-28. doi: 10.1016/j.jmb.2013.08.006. Epub 2013 Aug 13.

PMID:
23948507
17.

Formation of toxic oligomeric alpha-synuclein species in living cells.

Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ.

PLoS One. 2008 Apr 2;3(4):e1867. doi: 10.1371/journal.pone.0001867. Erratum in: PLoS One. 2008;3(5). doi: 10.1371/annotation/9282f173-df82-4b70-9120-b4e62b3dacb1.

18.

Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.

van Rooijen BD, Claessens MM, Subramaniam V.

Curr Protein Pept Sci. 2010 Aug;11(5):334-42. Review.

PMID:
20423294
19.

Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.

von Coelln R, Thomas B, Andrabi SA, Lim KL, Savitt JM, Saffary R, Stirling W, Bruno K, Hess EJ, Lee MK, Dawson VL, Dawson TM.

J Neurosci. 2006 Apr 5;26(14):3685-96.

20.

Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.

Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM.

Neuroscience. 2011 Dec 29;199:303-17. doi: 10.1016/j.neuroscience.2011.10.018. Epub 2011 Oct 20.

PMID:
22056602
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk